Programme Sunday, 14 May

Rejestracja

Sunday afternoon, 14 May, 15:00

Kolacja i Rejestracja

Sunday evening, 14 May, 19:00

Monday, 15 May

Śniadanie i Rejestracja

Monday morning, 15 May, 7:00

Otwarcie Konferencji

G. Grynkiewicz - Wystąpienie okolicznościowe; O. Achmatowicz - Rozstrzygnięcie "Konkursu o Nagrodę i Medal im. Stanisława Binieckiego"

Monday morning, 15 May, 8:30

9:00

Opening lecture

CAN A QUEST FOR A NEW DRUG OF POLISH ORIGIN BE SUCCESSFUL?

Wiesław Szelejewski

Instytut Farmaceutyczny (PRI), Rydygiera 8, Warszawa 01-793, Poland

E-mail: kontakt@ifarm.waw.pl

Sesja I

Monday morning, 15 May, 9:45

Chair: Aleksander P. Mazurek, Osman Achmatowicz

9:45

Invited Oral

THE LATEST ADVANCES IN CLINICAL GENETICS OF BREAST CANCER.

Jan Lubiński

Pomorska Akademia Medyczna, Zakład Genetyki i Patomorfologii, P.Wielkopolskich 72, Szczecin, Poland

E-mail: lubinski@sci.pam.szczecin.pl

Przerwa na kawę

Monday morning, 15 May, 10:30

Sesja I cd.

Monday morning, 15 May, 10:50

Chair: Aleksander P. Mazurek, Osman Achmatowicz

10:50

Oral


NEW DUAL 5-HT /5-HT LIGANDS WITH ANTIDEPRESSANT AND ANXIOLYTIC-LIKE

Andrzej J. Bojarski¹, Jan Boksa¹, Beata Duszyńska¹, Piotr Brański², Agnieszka Pałucha², Joanna Wierońska²

1. Institute of Pharmacology Polish Academy of Sciences, Department of Medicinal Chemistry, Smetna 12, Kraków 31-343, Poland 2. Institute of Pharmacology Polish Academy of Sciences, Department of Neurobiology, Smetna 12, Kraków 31-343, Poland

E-mail: bojarski@if-pan.krakow.pl

In the course of searching for the new, potent 5-HT antagonists, a group of 14 new tetrahydro-β-carboline derivatives with tetramethylene linker and different (cyclic imide/amide, benzotriazole) terminals were synthesized and evaluated for 5-HT and 5-HT receptor affinity. Compounds with ftalimide, indolinone and 8-azaspiro[4.5]decane-7,9-dione fragments were among the best 5-HT ligands and they also showed a significant activity for 5-HT receptors. For these selected compounds functional profile for 5-HT receptors was determined in adenylate cyclase assay, and their therapeutic potential was further examined in forced swimming, tail suspension and plus-maze tests. Of the analyzed ligands B1019 displayed antidepressant properties whereas for B991 anxiolytic-like activity was detected.



This study was partially supported by the research grant no. 012/2002 from the Polish Pharmacy and Medicine Development Foundation, given by the POLPHARMA Pharmaceutical Works.

11:10

Oral

NOVEL ANITIEPILEPTIC DRUG - DISCOVERY STORY AND PERSONAL REMARKS

Ryszard Andruszkiewicz

Gdansk University of Technology, Narutowicza 11/12, Gdańsk 80-952, Poland

E-mail: ryszarda@chem.pg.gda.pl

Novel drug, known under the brand name Lyrica and produced by Pfizer, has recently been approved for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia and adjunctive treatment of partial seizures in adults with epilepsy. It is currently available in about 25 countries and 25 more countries have approved it and should be selling it by summer this year. Lyrica